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Data regarding the tolerance of ACE inhibitors in
old age are sparse, despite this class of compound
being regarded as one of the first-line agents for
the treatment of hypertension. In the present trial,
the efficacy and tolerance of the ACE inhibitor
fosinopril was examined over a period of 12 weeks
in an open trial of hypertensive patients aged over
60 years with diastolic hypertension (diastolic
blood pressure 95 to 110 mm Hg) and isolated
systolic hypertension (ISH; systolic blood pressure
160 to 219 mm Hg, diastolic blood pressure 80 to 94
mm Hg). Fosinopril decreased blood pressure from
174/101 mm Hg to 149/88 mm Hg in patients with
diastolic hypertension and from 182/86 mm Hg to
151/80 mm Hg in patients with ISH. Seventy
percent of patients did not require any adaptation
of the initial fosinopril dose to achieve an
adequate therapeutic response. In the patients in
whom 20 mg fosinopril did not adequately reduce
blood pressure, the addition of 12.5 mg
hydrochlorothiazide was found to be slightly more
effective than doubling the initial dose of the ACE
inhibitor. Fosinopril was well tolerated and the
occurrence of drug-dependent side effects was not
increased in patients with renal insufficiency.
Fosinopril is an excellent therapy for the treatment
of hypertension in elderly patients, particularly
because, as a consequence of its dual,
compensatory excretion, no adaptation of the dose
is necessary, even in patients with a physiological
reduction in renal function. Am J Hypertens 1997;
10:255S–261S © 1997 American Journal of
Hypertension, Ltd.
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The prevalence of hypertension in the elderlyin the Western world is clearly on the in-crease, currently reaching a figure of 35% to45%.1–3 Apart from the total increase in sub-
jects aged .65 years, a number of additional factors
are responsible for the growth of the elderly hyper-
tensive population, particularly the problem of defini-
tion and the specific metabolic features associated
with old age.4 Hypertension in the elderly also pre-
sents particular problems in terms of diagnosis. Be-
cause of the reduced compliance of arterial vessels
observed in old age, systolic blood pressure is often
underestimated, whereas the diastolic blood pressure
is often overestimated.5,6 Since the middle of the
1980s, the Swiss Association against High Blood Pres-
sure (SVGHBD) has been calling for higher blood
pressure limits (. 180/100 mm Hg) as the therapeutic
threshold. The generally accepted World Health Or-
ganization (WHO) definition of arterial hypertension7
can only be regarded as conditionally applicable in old
age. Screening studies have revealed that increasing
age is more and more frequently accompanied by
isolated systolic hypertension (ISH; systolic blood
pressure $ 160 mm Hg and diastolic blood pressure ,
90 mm Hg).5,8 Many studies have stressed the need for
appropriate treatment of such hypertension to reduce
cardiovascular and cerebrovascular risk.4,9,10 In partic-
ular, the incidence of stroke can be reduced by anti-
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hypertensive therapy even in patients aged over 80
years9 and in addition, the Swedish Trial in Old Pa-
tients (STOP) study showed a clear reduction in total
mortality of 43% associated with antihypertensive
therapy.11
Hypertension in the elderly presents particular
problems in terms of diagnosis as the reduced com-
pliance of the arterial blood vessels in old age tends
to mean that systolic blood pressure is underesti-
mated, whereas diastolic blood pressure is overes-
timated.6,10 Older people frequently have a wide
range of other medical problems and accordingly
take more medicines. This polytherapy can increase
the incidence of drug-related side effects, partly
because of potential drug interactions, but also be-
cause drug accumulation can occur in association
with a physiological deterioration in the renal func-
tion with age.11 Recently, however, the European
Working Party on High Blood Pressure in the El-
derly (EWPHE) Trial noted a very low side effect
rate (8%) in elderly patients,12 and the STOP Trial
did not show an increased rate of withdrawal from
the trial in the treatment group as compared with
the placebo group.13
Drug-related adverse events have a major effect on
patient compliance. Elderly patients often have a range
of comorbid conditions and therefore frequently require
a number of different medications. Thus, an increased
incidence of side effects would be expected resulting
from altered pharmacokinetics, potential drug interac-
tions, and reduced kidney function associated with older
age.12 Until recently, patient compliance in the elderly
has been regarded as particularly poor. The Systolic
Hypertension in the Elderly Programme (SHEP) and
data from our own group has revealed a compliance
comparable with that of younger patients in similar cir-
cumstances.14,15 Whether or not elderly patients are less
compliant with long-term therapy, it is well established
that compliance can be improved by well tolerated med-
ication and by simple medication regimens.16–18
The efficacy of ACE inhibitors in elderly patients
with hypertension has been satisfactorily demonstrat-
ed.19–21 Very little is known, however, about the tol-
erability of ACE inhibitors in old age,19,20 despite the
fact that this class of compound must be regarded as
first-line agents for the treatment of hypertension in
the light of its mechanism of action.
The aim of the Fosinopril in Old Patients Study
(FOPS) trial was to examine the efficacy and tolerabil-
ity of the ACE inhibitor fosinopril in elderly hyperten-
sion patients with relatively normal renal history.
PATIENTS AND METHODS
In this open-label trial, carried out by 241 practicing
physicians in Switzerland, hypertensive men and
women aged 60 years or over were treated with fosi-
nopril. The inclusion and exclusion criteria are shown
in Table 1. The patient population was divided into
two groups on the basis of their hypertension: Group
1 with an increased diastolic blood pressure (95 to 110
mm Hg), and Group 2 with ISH (diastolic blood pres-
sure 80 to 94 mm Hg; systolic blood pressure 160 to
219 mm Hg) (Table 1).
At admission, subjects underwent clinical examina-
tion and laboratory tests prior to administration of the
study medication (20 mg fosinopril once daily in the
morning). Follow-up visits were made after 3, 6, and
12 weeks (the conclusion of the trial), during which
laboratory analyses and assessment of the efficacy and
tolerability were performed. During the third visit
(week 6) the fosinopril dose could be doubled if nec-
essary, or supplemented with 12.5 mg hydrochlorothi-
azide (HCTZ), to achieve better blood pressure con-
trol. This was recommended if the systolic blood pres-
sure remained .160 mm Hg and the diastolic blood
pressure remained .90 mm Hg.
The creatinine clearance in relation to sex, weight,
and serum creatinine was calculated by means of the
Cockcroft and Gault formula.22 Three prospectively
defined groups were formed on the basis of the calcu-
lated creatinine clearance: normal renal function (cre-
atinine clearance $ 80 mL/min); slight impairment of
renal function (creatinine clearance $ 50 and , 80
mL/min); and moderate or worse renal insufficiency
(, 50 mL/min).
The efficacy of fosinopril, the need for an increase in
medication, and the nature and frequency of side ef-
fects and their correlation with the degree of renal
function was analyzed on an ‘‘intention-to-treat’’ ba-
sis. Statistical evaluation of the results was carried out
by an external institute (Brunner & Hess, Software,
Zu¨rich), using the SPSS Programme. The Wilcoxon
TABLE 1. ADMISSION AND EXCLUSION
CRITERIA IN THE FOSINOPRIL IN
OLD PATIENTS (FOPS) TRIAL
Admission criteria
Age $60 years
Informed consent
Group 1: Diastolic blood pressure 95–110 mm Hg
Group 2: Diastolic blood pressure 80–94 mm Hg
Systolic blood pressure 160–219 mm Hg
Exclusion criteria
Age ,60 years
Diastolic blood pressure .110 mm Hg
Systolic blood pressure $220 mm Hg
Inadequately controlled Diabetes mellitus
Serum creatinine . 180mmoL/1
An established exclusion criterion for administration of
an ACE inhibitor
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test and the Student t test were used for assessing the
variation in the mean blood pressure.
RESULTS
Patients A total of 757 patients were enrolled in the
trial: 649 (85.7%) in Group 1 (diastolic hypertension)
and 108 (14.3%) in Group 2 (ISH). Sixty-three percent
of the participants were female. The demographics of
the patient groups are shown in Table 2. A total of 532
(82%) patients in Group 1 and 96 (89%) patients in
Group 2 completed the full 12 weeks of the trial; 75
patients withdrew from the trial as a result of side
effects, 28% because of inadequate compliance, and
the remainder for other reasons.
TABLE 2. DEMOGRAPHICS OF PATIENTS COMPLETING FOPS
Group 1 Group 2
TotalWomen Men Women Men
No. of subjects 331 201 60 36 628
Age (years; mean 6 SD) 69.7 (69) 67.1 (610) 73.7 (67) 69.6 (69) 62.9 (69)
BMI* (kg/m2) 27.3 27.6 26.5 26.5 27.2
BMI* , 27.3 kg/m2 (%) 59 59 59 64 59
BMI* $ 27.3 kg/m2 (%) 41 41 41 36 41
Systolic BP (mm Hg) 175 172 182 182 175
Diastolic BP (mm Hg) 101 101 86 86 98
Serum creatinine (mmol/L) 91 101 92 99 —
Creatinine clearance (mL/min) 61 76 56 69 66
Blood potassium (mmol/L) 4.32 4.44 4.34 4.29 4.36
Total cholesterol (mmol/L) 6.45 6.07 6.16 6.00 6.27
Triglycerides (mmol/L) 1.80 1.94 1.69 1.86 1.84
No. of patients receiving previous treatment 190 92 30 19 331
Concomitant conditions 176 110 34 18 338
None (%) 46.8 45.3 43.3 50.0 46.2
Diabetes mellitus (%) 4.5 10.4 5.0 5.6 6.5
Lipid disorders (%) 4.5 6.0 6.7 0.0 6.5
Obesity (%) 68.5 8.0 3.3 2.8 7.5
Cardiac symptoms (%) 6.6 6.5 13.3 11.1 7.6
* BMI, body mass index.
FIGURE 1. Blood pressure response in patients on fosinopril by group. (Group 1: DBP # 90 mm Hg; Group 2: SBP # 160 mm Hg).
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Efficacy A good antihypertensive response to fosi-
nopril was obtained in Group 1, with reduction in the
blood pressure from 174/101 mm Hg to 149/88 mm
Hg after 12 weeks (Figure 1). The greatest reduction in
blood pressure, both systolic and diastolic, was
achieved during the first 3 weeks. In Group 2, a
marked reduction in systolic blood pressure was ob-
tained, whereas the decrease in diastolic blood pres-
sure was not statistically significant (182/86 mm Hg v
151/80 mm Hg) (Figure 1).
It was not necessary to increase the initial dose of
fosinopril (20 mg once daily) in 70% of the patients.
After 12 weeks, blood pressure reached normal val-
ues in 82% of patients in Group 1 and 84% of the
patients in Group 2. Fifty-two percent of the pa-
tients in Group 1 and 64% of the patients in Group
2 had a normalization of blood pressure following
an increase in the initial fosinopril dose (to 40 mg
once daily) and 68% and 67% of patients, respec-
tively, had a normalization of blood pressure fol-
lowing supplementation with 12.5 mg HCTZ. All
decreases in blood pressure values from baseline
were statistically significant, with the exception of
the decrease in diastolic blood pressure in patients
with ISH receiving fosinopril 40 mg/day or fosino-
pril in combination with HCTZ.
Side Effects A total of 219 incidences of side effects
were recorded in 149 of 757 patients (19.7%) during
the observation period (Figure 2). The incidences of
side effects were 19.0% in Group 1 and 24.1% in
Group 2, and women reported side effects more
frequently than did men (22.4% v 15.1%). In both
groups, cough was the most frequently reported
side effect (6.3% and 6.5% in Group 1 and Group 2,
respectively), followed by gastrointestinal com-
plaints (4.9% v 8.5%) and dizziness (2.2% v 3.7%). In
addition, increased fatigue was reported in 5.6% of
the patients in Group 2. Hypotension was reported
only four times (0.6%) in Group 1 and was not
reported in Group 2. A slightly higher side effect
rate was reported when the fosinopril dose was
increased from 20 mg to 40 mg (14.3% v 10.5%), as
well as in patients treated with fosinopril/HCTZ
(15.9%) (Figure 2).
Seventy-five patients (54 women and 21 men) with-
drew from treatment as a result of the occurrence of
126 (97 in women, 29 in men) side effects during the
trial. Coughing and gastrointestinal complaints were
the most frequently reported events.
Renal Dysfunction The demographics of the pa-
tients divided into three groups by their calculated
creatinine clearance values are shown in Table 3. More
than three-quarters of the patients included in the
trial, with no history of renal disease, were found to
have at least a minor reduction in renal function.
Astonishingly, the side effect rates in all three renal
functional groups were virtually identical, and no cor-
relation was found during treatment between the fre-
quency of side effects and the degree of reduction of
renal function. As is evident in Table 3, only gastroin-
testinal symptoms and fatigue/weakness were re-
ported more often with increasing impairment of renal
function; however, this was not statistically signifi-
cant. The proportion of patients aged $ 70 years and
the proportion of women were highest in the group
with low creatinine clearance.
DISCUSSION
The aim of the FOPS study was to investigate the
efficacy and tolerability of fosinopril in elderly hyper-
TABLE 3. PRINCIPAL CLINICAL DATA BY CREATININE CLEARANCE VALUES
Creatinine Clearance <50 mL/min 50–79 mL/min >80 mL/min
Patients (%) 24 54 22
Mean creatinine clearance (mL/min) 40.0 63.7 96.5
Sex (male/women; %) 21/79 35/65 63/37
GI side effects (%) 8.8 5.8 2.4
Fatigue/weakness (%) 3.3 1.0 0.5
FIGURE 2. Nature and frequency of reported side effects as a
function of treatment regimen.
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tensives without a history of renal disease. The initial
dose of 20 mg of fosinopril was sufficient to achieve a
normal blood pressure in two-thirds of the patients
after 3 weeks, without additional modification of the
therapeutic regimen throughout the remainder of the
study period. The antihypertensive efficacy of fosino-
pril was good in older patients with both diastolic and
systolic hypertension, with the reduction in blood
pressure comparable to that of diuretics or b-block-
ers.4,11 The ACE inhibitor/diuretic combination was
slightly more effective than was 40 mg of fosinopril, a
finding that has already been reported in the litera-
ture.23 In view of the stimulation of the renin-angio-
tensin-aldosterone system by the diuretic, combina-
tion with an ACE inhibitor has a synergistic effect,
with the increased renin production from the juxtaglo-
merular apparatus providing the ACE inhibitor with
more substrate.
Fosinopril was well tolerated, and its side effect
profile, as shown in Figure 2, largely corresponded to
that previously reported. As described in the litera-
ture, cough was the most frequent side effect24,25 and
was also the most frequent cause of withdrawal from
the trial. This finding again indicates that this side
effect is group-specific,26,27 even though cough may be
less likely to occur with fosinopril than with other
ACE inhibitors.24,25
In contrast to data in the literature,28 very few cases
of hypotension were recorded in this trial, although
the chosen starting was relatively high (in general,
treatment initiation with a starting dose of 10 mg is
recommended as it has been shown to be an effective
dose).
In FOPS, the reduction in creatinine clearance with
increased age was very apparent (Figure 3). In the
present trial, only 25% of the patients aged .60 years
had a normal creatinine clearance. Attention should
again be drawn to the discrepancy between serum
creatinine and creatinine clearance that is due to the
smaller muscle volume in older patients.29 The phys-
iological reduction of renal function in old age is,
however, subject to marked intersubject variability,
making it impossible to generally predict the time at
which dose adjustment may be necessary for any med-
ication.
The reduced renal function in old age is of particu-
lar importance in connection with ACE inhibitors.30
ACE inhibitors are, in general, excreted via the kid-
FIGURE 3. Comparison of serum creatinine with creatinine clearance.
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neys, mainly from the tubules in the form of acids.31,32
If renal function is reduced, there is a risk of accumu-
lation of the active agent and an increase in the blood
pressure reduction as well as an increased frequency
of drug-related side effects.33–38 In contrast to other
ACE inhibitors currently available, fosinopril has a
unique pattern of excretion. After ingestion, fosinopril
is rapidly converted into fosinoprilat or its conjugated
glucuronide, which are excreted via the kidneys or in
the bile. In a patient with normal renal function, ap-
proximately 50% of fosinoprilat is excreted by the
kidney and 50% by the liver.39 When the excretion
capacity of the kidneys or of the liver is reduced,
the other organ compensates with increased excre-
tion.40,41 Therefore, there is risk of drug accumulation
only when both organs have a substantially restricted
function.42,43
There was no difference in either the side effect rate
or the withdrawal rate from the trial among groups
with creatinine clearance rates of ,50, 50 to 79, and
$80 mL/min. Only gastrointestinal side effects and
fatigue/weakness showed a tendency to increase with
deterioration in renal function. It is important to note,
however, that the proportion of women and of pa-
tients .75 years old, both of which are populations
known to have increased side effect rates, were over-
represented in the low creatinine clearance group. In
addition, there was a lack of dose-dependency in treat-
ment discontinuation. Therefore, fosinopril’s compen-
satory dual excretion mechanism prevented accumu-
lation of the compound, even in patients with medium
to severe renal insufficiency. This is of particular ad-
vantage in older patients, in whom reduced renal
function is frequently undiagnosed, particularly as
‘‘normal’’ serum creatinine level may not reflect nor-
mal creatinine clearance.
In this unselected, Swiss population of hyperten-
sive patients aged $60 years, with no prior history
of renal disease, at least minor renal insufficiency
was found to be present in approximately 75% of
patients. The efficacy of fosinopril in a relatively
high initial dose of 20 mg once daily was found to be
good both in patients with diastolic hypertension
and in those with ISH. When increased medication
was required to control blood pressure, the results
showed that combination with a diuretic was
slightly more effective than was doubling the fosi-
nopril dose. The compensatory, dual excretion
mechanism of fosinopril appears to be advanta-
geous in daily practice, because the physiological
reduction in the renal function with age did not
necessitate any adjustment of the fosinopril dose,
nor did it lead to a greater incidence of side effects.
To verify the findings of this trial, it would be de-
sirable to undertake a direct comparison of fosinopril
with an ACE inhibitor excreted exclusively via the
renal route.
SUMMARY
It was only at the beginning of the 1990s that the need
for considering antihypertensive treatment in many
elderly patients was recognized. A consistent means
of reducing blood pressure in elderly patients is de-
sirable, in order to prevent cardiovascular accidents.
In the present trial, the efficacy and tolerability of the
ACE inhibitor fosinopril was examined over a period
of 12 weeks, in an unselected outpatient trial in hy-
pertensive patients aged $60 years. Subjects with di-
astolic hypertension (diastolic blood pressure 95 to 110
mm Hg) and ISH (systolic blood pressure $ 160 to 219
mm Hg, diastolic blood pressure 80 to 94 mm Hg)
were examined separately. Blood pressure was nor-
malized in more than 80% of patients in both groups.
If the initial response was inadequate, the addition of
12.5 mg hydrochlorothiazide was found to be slightly
more effective than was doubling the initial dose of
the ACE inhibitor.
The occurrence of side effects was minimal and was
not related to creatinine clearance. The compensatory
dual excretion mechanism of fosinopril was of impor-
tance, as no adjustment of the dose was necessary
even in patients with reduced renal function.
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